Arnovie-101

N/A

Report date: 2026/04/09 20:00:21

Base Information

Drug NameArnovie-101
Drug Alias NameArnovie-101Arnovie101
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy > LNPCell and gene therapy > Gene therapy > mRNA
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsAutoimmune DiseasesLupus Erythematosus, SystemicAnemia, Hemolytic, Autoimmune
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJiuke Runjia Biopharmaceutical (Shenzhen) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesJiuke Runjia Biopharmaceutical (Shenzhen) Co Ltd
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesLupus Erythematosus, SystemicAnemia, Hemolytic, Autoimmune
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A